Evidence map›Paper›PMID 29379766›Full record

ArticleSchizophrenia research. Cognition2015

Different P50 sensory gating measures reflect different cognitive dysfunctions in schizophrenia.

Atsuhito Toyomaki, Naoki Hashimoto, Yuki Kako, Yoshiro Tomimatsu, Tsukasa Koyama, Ichiro Kusumi

Abstract read
In one paragraph

Article in Schizophrenia research. Cognition, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Atsuhito ToyomakiDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.
Naoki HashimotoDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.
Yuki KakoDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.
Yoshiro TomimatsuDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.
Tsukasa KoyamaDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.
Ichiro KusumiDepartment of Psychiatry, Graduate School of Medicine, Hokkaido University, N15, W7, Sapporo, 060-8638, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The P50 is an early component of auditory evoked potentials and a measure of sensory gating deficits. This evoked potential component is thought to be an important endophenotype candidate for schizophrenia. Recent research suggests that instead of the P50 ratio, S1 and S2 amplitudes should be evaluated for sensory gating. However, no studies have focused on the relationship between cognitive dysfunction and P50 sensory gating deficits using S1 and S2 amplitudes. The purpose of the present study was to investigate the association between the P50 ratio (S2/S1), S1 and S2 amplitudes, and neuropsychological cognitive domains using stepwise multiple linear regression analyses. Results demonstrated a significant relationship between executive functioning and the P50 ratio and between sustained attention and S2 amplitude, respectively. Our findings suggest that the P50 ratio and S2 amplitude reflect distinct neurophysiological substrates associated with different cognitive functions.

Indexed as

Cognitive dysfunctionP50SchizophreniaSensory gating

Identifiers

PMID29379766
PMCPMC5779302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.